Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Candidiasis, Invasive: later-stage trial registry
1 of 2 indexed Candidiasis, Invasive trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Candidiasis, Invasive: 2 US clinical trials tracked, 1 recruiting.
Candidiasis, Invasive is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Astellas Pharma, running 1 of these trials.
Enrollment posture brief
Registry condition candidiasis-invasive
OPEN 1 | RECR 50% | LATE 2 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Candidiasis, Invasive lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Candidiasis, Invasive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Candidiasis, Invasive is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Basilea Pharmaceutica
NCT05421858
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Astellas Pharma
NCT00413218
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Candidiasis, Invasive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Candidiasis, Invasive trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Candidiasis, Invasive page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Candidiasis, Invasive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Astellas Pharma sponsors the most Candidiasis, Invasive trials on record, review their full trial history before evaluating a specific study. See Astellas Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Candidiasis, Invasive condition card totals 2 registered trials; most-linked intervention Caspofungin; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.